Article Data

  • Views 289
  • Dowloads 135

Reviews

Open Access

Serum markers as prognostic factors in epithelial ovanan cancer: an overview

  • T. Maggino1,*,
  • A. Gadducci2

1Department of Gynaecology and Obstetrics, University of Padua, Italy

2Department of Reproductive Medicine, Division of Gynecology and Obstetrics, University of Pisa, Italy

DOI: 10.12892/ejgo20000164 Vol.21,Issue 1,January 2000 pp.64-69

Published: 10 January 2000

*Corresponding Author(s): T. Maggino E-mail:

Abstract

A comprehensive review of the literature and the authors' personal experience on serum determination of tumour markers in epithelial ovarian cancer can be summarised as follows: CA 125 is the most reliable marker for monitoring the course of epithelial ovarian cancer; CA 125 assay is not an adequate screening test for this malignancy but it can represent an useful adjunct to clinical examination and ultrasound in the differential diagnosis of ovarian masses in postmenopausal women; Serial measurements of CA 125 are useful in monitoring the response to chemotherapy and follow-up. In patients with preoperative positive CA 125 assay, the concomitant determination of other tumour markers does not add further information when compared to CA 125 alone. Conversely in patients with preoperative negative assay the measurement of one or more of other antigens could be of clinical relevance.

Cite and Share

T. Maggino,A. Gadducci. Serum markers as prognostic factors in epithelial ovanan cancer: an overview. European Journal of Gynaecological Oncology. 2000. 21(1);64-69.

References

[1] Bast R. C. Jr, Feeney M., Lazarus H., Nadler L. M., Colvin R. B., Knapp R. C.: "Reactivity of a monoclonal antibody with human ovarian carcinoma". J. Clin. Invest., 1981, 68, 1331.

[2] Jacobs I., Bast R. C. Jr:'The CA 125 tumour-associated antigen: a review of the literature". Hum. Reprod., 1989, 4, 1.

[3] NHI Consensus Conference. Ovarian cancer. Screening, treatment, and follow-up". JAMA, 1995, 273, 491.

[4] Masahashi T., Matsuzawa K., Ohsawa M., Narita O., Asai T., Ishihara M.: "Serum CA 125 levels in patients with endometriosis: Changes in CA 125 levels during menstruation". Obstet. Gynecol., 1988, 72, 328.

[5] Halila H. Stenman U. H., Seppala M.: "Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy". Cancer, I 986, 57, 1327.

[6] Kabawat S. E, Bast R. c. Jr, Wclch W. R,,knapp R C, Colvin R. B.: "Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid and clear cell types". Am. J. Clin. Pathol., 1983, 79, 98.

[7] Shishi J., Ghazizadeh M., Oguro T.,心hara K., Araki T.: "Immunohistochemical localization of CA 125 antigen in formalin-fixed paraffin sections of ovarian tumors with the use of Pronase". Am. J. Clin. Pathol., 1986, 85, 595.

[8] Einhorn N., Bast R. C. Jr, Knapp R. C., Tjernberg B., Zurawski V. R. jr: "Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer". Obstet. Gynecol., 1986, 67, 414.

[9] Zurawski V. R. Jr, Knapp R. C., Einhorn N., Kenemans P., Mortel R., Ohmi K., Bast R. C. Jr et al.: "An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma". Gynecol. Oneal., 1988, 30, 7.

[10] Gadducci A., Ferdeghini M., Prontera C., Moretti L., Mariani G., Bianchi R., Fioretti P.: "The concomitant determination of different tumor markers in patients with epitelial ovarian cancer and benign ovarian masses: Relevance for differential diagnosis". Gynecol. Oneal., 1992, 44, 147.

[11] Vasilev S. A., Schlaerth J. B., Campeau J.,M orrow C. P.: "Serum CA 125 levels in preoperative evaluation of pelvic masses". Obstet. Gynecol., 1988, 71, 751.

[12] Malkasian G. D. Jr, Knapp R. C., Lavin P. T., Zurawski V. R. Jr, Podratz K. C., Stanhope R.,M ortel R. et al.: "Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease". Am. J. Obstet. Gynecol., 1988, 159, 341.

[13] Di-Xia C., Schwartz P. E., Xinguo L., Zhan Y.: "Evaluation of CA 125 levels in differentiating malignant from benign tumors iri patients with pelvic masses". Obstet. Gynecol., 1988, 72, 23.

[14] Soper J. T.,H unter V. J.,D aly L.,T anner M.,C reasman W.T., Bast R. C. Jr: "Preoperative serum tumor-associated i antigen levels in women with pelvic masses". Obstet. Gynecol., 1990, 75, 249.

[15] Finkler N. J.,B enacerraf B.,L avin P. T.,W ojciechowski C., Knapp R. C.: "Comparison of serum CA 125, clinical impression and ultrasound in the preoperative evaluation of ovarian masses". Obstet. Gynecol., 1988, 72, 659.

[16] Gadducci A., Capriello P., Ferdeghini M., Licata L., Puccetti A.,M adrigali A., Bianchi R.,F ioretti P.: "The combined evaluation of ultrasound, serum CA 125 assay and serum CA 19-9 assay in discriminating a benign from a malignant ovarian mass". Cancer J., 1990, 3, 252.

[17] Maggino T., Gadducci A., D'Addario V., Pecorelli S., Lissoni A., Stella M., Romagnolo C. et al.: "Prospective multicenter study on CA 125 in postmenopausal pelvic masses". Gynecol. Oncol., 1994, 54, 117.

[18] SchutterE.M . J.,K enemans P.,S ohn C.,K ristenP.,C rombach G.,W estermann R.,M obus V. et al.: "Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass". Cancer, 1994, 74, 1398.

[19] Strigini F. A. L., Gadducci A., Del Bravo B., Ferdeghini M., Genazzani A. R.: "Differential diagnosis of adnexal masses with transvaginal sonography, color flow imaging, and serum CA 125 assay in pre- and postmenopausal women". Gynecol. Oncol., 1996, 61, 68.

[20] Bast R. C. Jr, Klug T. L., Schaetzl E., Lavin P., Niloff J.M., Greber T. F., Zurawski V. R. Jr, Knapp R. C.: "Monitoring human ovarian carcinoma with a combination of CA 125, CA 19.9 and carcinoembryonic antigen". Am. J. Obstet. Gynecol., 1984, 149, 553.

[21] Canney P. A.,M oore M., Wilkinson P. M., James R. D.: "Ovarian cancer antigen CA 125: A prospective clinical assessment of its role as a tumour marker". Br. J. Cancer, 1984, 50, 765.

[22] Halila H., Lehtovirta P., Stenman U. H.: "Tumor-associated trypsin inhibitor (TATI) in ovarian cancer". Br. J. Cancer, 1988, 57, 304.

[23] Fioretti P., Gadducci A., Ferdeghini M., Prontera C., Malagnino G.,F acchini V.,M ariani G.,B ianchi R.: "The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients". Gynecol. Oncol.,1992, 44, 155.

[24] Atack D. B., Nisker J. A., Allen H. H., Tustanoff E. R., Levin L.: "CA 125 surveillance and second-look laparotomy in ovarian carcinoma". Am. J. Obstet. Gynecol., 1986, 154, 287.

[25] Schilthuis M. S.,A alders J. G.,B ouma J.,K ooi H.,F leuren G. J., Willemse P.H. B., De Bruijn H. W. A. Serum CA 125 levels in epithelial ovarian cancer. Relation with findings at second-look operations and their role in the detection of tumour recurrence". Br. J. Obstet. Gynaecol., 1987, 94, 202.

[26] Podczaski E., Whitney C., Manetta A., Larson J.E., Kirk J., Stevens C. W., Lyter J.,M ortel R.: "Use of CA 125 to monitor patients with ovarian epithelial carcinomas". Gynecol. Oncol., 1989, 33, 193.

[27] Lavin P. T., Knapp R. C.,M alkasian G., Whitney C. W., Berek J. C., Bast R. C. Jr: "CA 125 for the monitoring of ovarian carcinoma during primary therapy". Obstet. Gynecol., 1987, 69, 223.

[28] Mogensen 0.,M ogensen B.,J akobsen A.: "Predictive value of CA 125 during early chemotherapy of advanced ovarian cancer". Gynecol. Oneal., 1990, 37, 44.

[29] Hawkins R. E., Roberts K., Wiltshaw E., Mundy J., Fryatt I. J.,M cCready V. R.: "The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma". Br. J. Obstet. Gynaecol., 1989, 96, 1395.

[30] Gadducci A., Zola P., Landoni F.,M aggino T., Sartori E., Bergamino T., Cristofani R.: "Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: "Results of a multicentric Italian study". Gynecol. Oneal., 1995, 58, 42.

[31] Niloff J. M., Knapp R. C., Lavin P. T.,M alkasian G. D., Berek J. S.,M ortel R., Whitney C. et al.: "The CA 125 assay has a predictor of clinical recurrence in epithelial ovarian cancer". Am. J. Obstet. Gynecol., 1986, 155, 56.

[32] Zanaboni F., Presti M., Scarfone G., Bolis G.: "CA 125 reliability in predicting ovarian cancer recurrence". Tumori, 1989, 75, 69.

[33] van der Burg M. E. L., Lammes F. B., Verweij J.: "The role of CA 125 in early detection of progressive disease in ovarian cancer". Ann. Oneal., 1990, 1, 301.

[34] Hogberg T., Kagedal B.: "Long-term follow-up of ovarian cancer with monthly determinations of serum CA 125". Gynecol. Oneal., 1992, 46, 191.

[35] Rustin G. J. S.,v an der BurgM . E. L.,B erek J. S.: "Tumour markers". Ann. Oneal., 1993, 4 (Suppl. 4), 71.

[36] Forstner R.,H ricak H., Powell C. B., Azizi L.,F rankel S. B., Stem J. L.: "Ovarian cancer recurrence: Value of M. R. Imaging". Radiology, 1995, 196, 715.

[37] Gadducci A., Sartori E., Zola P., Landoni F.,M aggino T., Palai N. Fanucchi A., Katsaros D.: "Serum CA 125 assay in the early diagnosis of recurrent epithelial ovarian cancer: a CTF study". Oneal. Rep., 1996, 3, 301.

[38] Cruickshank D. J.,F ullerton W. T., Klopper A.: "The clinical significance of pre-operative serum CA 125 in ovarian cancer". Br. J. Obstet. Gynaecol., 1987, 94, 692.

[39] Sevelda P., Schemper M., Spona J.: "CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer". Am. J. Obstet. Gynecol., 1989, 161, 1213.

[40] Maak r A. P.,K ristensen G. B.,K aem J.,Bormer O. P.,A beler V. M., Trope C. G.: "Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: New aspects and multivariate analysis". Obstet. Gynecol., 1992, 79, 1002.

[41] Mobus V., Kreienburg R., Crombach G.: "Evaluation of CA 125 as a prognostic and predictive factor in ovarian cancer". J. Tumor Marker Oncol., 1988, 3, 251.

[42] Rosen A., Sevelda P., Klein M., Spona J., Beck A.: "A CA 125 score as a prognostic index in patients with ovarian cancer". Arch. Gynecol. Oncol., 1990, 247, 125.

[43] Cruickshank D. J.: "CA 125 parameters in survivors and nonsurvi vors with epithelial ovarian cancer". Int. J.

Gynecol. Cancer, 1991, 1, 279.

[44] Brand E., Lidor Y.: "The decline of CA 125 level after

surgery reflects the size of residual ovarian cancer". Obstet.

Gynecol., 1993, 81, 29.

[45] Yedema C., Kenemans P., T homas C., Massunger L., Wobbes T. H.,V erstraeten A.,V an Kamp G.,H ilgers J.: “CA l25 serum levels in the early post-operative period do not reflect tumor reduction obtained by cytoreductive surgery". Eur. J. Cancer, 1993, 29, 966.

[46] Gadducci A., Landoni F., Maggino T., Sartori E., Zola P., Fanucchi A.: "The relationship between postoperative decline of serum CA 125 levels and size of residual disease after initial surgery in patients with advanced ovarian cancer: A CTF study". Gynecol. Oncol., 1996, 63, 234.

[47] Redman C. W. E.,J ones S. R.,L uesly D. M.,N icholl S. E., Kelly K., Buxton E. J., Chan K. K., Blackledge G. R. P.: "Peritoneal trauma releases CA 125?". Br. J. Cancer, 1988, 58,502.

[48] Talbot R. W., Jacobsen D. J., Nagomey D. M., Malkasian G. D., Ritts R. E.: "Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer". S urg. Gynecol. Obstet., 1989, 168, 407.

[49] Van der Zee A. G. J., Duk J. M., Aalders J. G., Boontje A. H., Ten Hoor K. A., De Bruijn H. W. A.: "The effect of abdominal surgery on the serum concentration of the tumorassociated antigen CA 125". Br. J. Obstet. Gynaecol., 1990, 97, 934.

[50] Fayers P. M., Rustin G., Wood R., Nelstrop A., Leonard R. C. F., Wilkinson P., Cruickshank D. et al.: "On behalf of the MRC Working Party on Gynaecological Cancer. The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer". Int. J. Gynecol. Cancer, 1993, 3, 285.

[51] van der Burg M. E. L., Lammes F. B., van Putten W. L. J., Stoter G.: "Ovarian cancer: The prognostic value of the serum half-life of CA 125 during induction chemotherapy". Gynecol. Oncol., 1988, 30, 307.

[52] Hunter V. J., Daly L., Helms M., Soper G. T., Berchuck A., Clarke-Pearson D. L., Bast R. C. Jr: "The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction". Am. J. Obstet. Gynecol., 1990, 163, 1164.

[53] Hogberg T., Kagedal B.: "Serum half-life of the. tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma". Acta Obstet. Gynecol. Scand., 1990, 69, 423.

[54] Makar A. P., Kristensen G. B., Bormer 0. P., Trope C. G.: "Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?" Gynecol. Oncol., 1993, 49, 3.

[55] Gadducci A., Landoni F., Maggino T., Sartori E., Zola P., F erdeghini M., Parma G., Cristofani R.: "Serum CA 125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study". Int. J. Gynaecol. Cancer, 1997, 7, 78.

[56] Yabushita H., Masuda T., Ogawa A., Noguchi M., Ishihara M.: "Combination assay of CA 125, TPA, IAP, CEA, and ferritin in serum for ovarian cancer". Gynaecol. Oncol., 1988, 29, 66.

[57] Fioretti P., Gadducci A., F ederghini M., Bianchi R.: "Tumor marker association in ovarian and cervical cancer". In: "Up dating on tumor markers in tissues and in biological fluids. Basic aspects and clinical applications". (Ballesta A. M., Torre G. C., Bombardieri E., Gion M., Molina R. eds), Edizioni Minerva Medica, Torino, 1993, 737.

[58] Koprowski H., Steplewski Z., Mitchell K., Herlyn M., Herlyn D., F uhrer J. P.: "Colorectal carcinoma antigens detected by hybridoma antibodies". Somatic Cell Genet., 1979, 5, 957.

[59] Charpin C., Bhan A. K., Zurawski V. R. Jr, Scully R. E.: "Carcynoembryonic antigen (CEA) and carbohydrate determinant 19.9 (CA 19.9): Localization in 121 primary and metastatic ovarian tumors. An immunohistochemical study with use of monoclonal antibodies". Int. J. Gynecol. Pathol., 1982, 1, 231.

[60] Kufe D., Inghirami G., Abe M., Hayes P., Justi-Wheeler H., Schlom J.: "Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumor". Hybridoma, 1984, 3, 223.

[61] Hilkens J., Kroezen V., Bonfrer J. M. G., De Jong-Bakker M., Bruning P. F.: "MAM-6 antigen, a new serum marker for breast cancer monitoring". Cancer Res., 1986, 46, 2582.

[62] Paterson A. J., Schlom J., Sears H. F., Bennett J., Cokcher D.: "A radioimmunoassay for the detection of a human tumor-associated glycoprotein (TAG-72) using monoclonal antibody B72-3. Int. J. Cancer, 1986, 37, 659.

[63] Thor A., Gorstein F., Ohuchi N., Szpak C. A., Johnston W. W., Schlom J.: "Tumor associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72- 3". J. Natl. Cancer Inst., 1986, 76, 995.

[64] Canney P. A., Wilkinson P. M., James R. D., Moore M.: "CA 19.9 as a marker for ovarian cancer: alone and in comparison with CA 125". Br. J. Cancer, 1982, 52, 131.

[65] Scambia G., Benedetti-Panici P., Baiocchi G., Perrone L., Greggi S., Mancuso S.: "CA 15-3 as a tumor marker in gynecological malignancies". Gynaecol. Oneal., 1988, 30, 265.

[66] Gadducci A., Capriello P., F erdeghini M., Madrigali A., Puccetti A., Annichiarico C., Prontera C. et al.: "Pelvic ultrasound, serum CA 125 assay, CA 19-9 assay and serum CA 72-4 assay in the differential diagnosis of ovarian masses". Cancer J., 1991, 4, 249.

[67] Maggino T., Gadducci A., D'Addario V., Pecorelli S., Lissoni A., Stella M., Romagnolo C. et al.: "Prospective multicenter study on the clinical utility of CA 72.4 in postmenopausal patients with pelvic masses". Oneal. Rep., 1995, 2, 1069.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top